Cephalon's Provigil to piggyback Rozerem in promotion deal

Share this article:
In hopes of gaining marketing momentum from the push behind Rozerem, Cephalon has entered into agreement with Takeda Pharmaceutical to co-promote the biotech firm’s first-in-class wakefulness drug Provigil (modafinil) in the US, alongside the Takeda sleeping pill.  Beginning in July, 500 Takeda sales reps will also begin promoting Provigil, boosting the total Provigil sales force to 900 people. The one-way co-promotion agreement will run for three years with an option to renew annually. As part of the deal, Cephalon will also be given the option to utilize the Takeda sales force for the promotion of Nuvigil (armodafinil) tablets, a single-isomer formulation of modafinil, the active pharmaceutical ingredient contained in Provigil, awaiting FDA approval. Cephalon will pay Takeda a royalty based on certain sales criteria for Provigil and Nuvigil, the companies said. Additionally, Cephalon will retain all responsibility for development, manufacturing, distribution and sale of Provigil, with both companies to form a joint commercial committee to manage Provigil promotion. Mark Booth, president of Takeda Pharmaceuticals North America said in a statement, “Adding Provigil to our new central nervous system portfolio and having our representatives promote it alongside Takeda's Rozerem will be of great value to physicians and patients because of the respective roles of each product in the sleep-wake cycle.” Provigil is a first-in-class medication in a new class of wake- promoting drugs designed to work selectively through the sleep/wake centers to activate the cortex of the brain. In 2004, the FDA approved Provigil for improving wakefulness in patients with excessive sleepiness associated with shift work sleep disorder and as an adjunct to standard therapies for obstructive sleep apnea/hypopnea syndrome. Provigil was originally approved in 1998 for improving wakefulness in patients with excessive sleepiness associated with narcolepsy.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.